Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
ThymicPeptides Reverse Immune Exhaustion in Patients with Reactivated Human Alphaherpesvirus1 Infections.
Int J Mol Sci
March 2020
Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, 20-093 Lublin, Poland.
Recurrent infection with human alphaherpesvirus 1 (HHV-1) may be associated with immune exhaustion that impairs virus elimination. Thymic peptides enhance immune function and thus could overcome immune exhaustion. In this study, we investigated whether reactivation of herpes infections was associated with immune exhaustion.
View Article and Find Full Text PDFThymosin α 1: a novel therapeutic option for patients with refractory chronic purulent rhinosinusitis.
Ann N Y Acad Sci
October 2012
Department of Immunology, Erasmus Medical Center, Rotterdam, the Netherlands.
Chronic purulent rhinosinusitis (CPR) is an inflammatory condition of unknown origin. Although various medical and surgical treatment modalities are available, 5-10% of patients remain refractory. Immune deficiency is one of the underlying risk factors for this disease.
View Article and Find Full Text PDFThymic peptides for treatment of cancer patients.
Cochrane Database Syst Rev
February 2011
Medizinische Klinik 5-Schwerpunkt Onkologie/Haematologie, Klinikum Nord, Prof.-Ernst-Nathan-Str. 1, Nuernberg, Germany, D-90419.
Background: Purified thymus extracts (pTE) and synthetic thymic peptides (sTP) are thought to enhance the immune system of cancer patients in order to fight the growth of tumour cells and to resist infections due to immunosuppression induced by the disease and antineoplastic therapy.
Objectives: To evaluate the effectiveness of pTE and sTP for the management of cancer.
Search Strategy: We searched CENTRAL (The Cochrane Library 2010, Issue 3), MEDLINE, EMBASE, AMED, BIOETHICSLINE, BIOSIS, CATLINE, CISCOM, HEALTHSTAR, HTA, SOMED and LILACS (to February 2010).
Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial.
BMC Cancer
August 2010
Department of Medicine I, Martin-Luther-University Halle-Wittenberg, Germany.
Background: Thymostimulin is a thymic peptide fraction with immune-mediated cytotoxicity against hepatocellular carcinoma (HCC) in vitro and palliative efficacy in advanced HCC in two independent phase II trials. The aim of this study was to assess the efficacy of thymostimulin in a phase III trial.
Methods: The study was designed as a prospective randomised, placebo-controlled, double-blind, multicenter clinical phase III trial.
Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials.
J Hepatol
July 2010
Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
Background & Aims: Predniso(lo)ne with or without azathioprine is considered the mainstay in the treatment of autoimmune hepatitis (AIH), but many therapeutic options are available. The primary objective of this review was to explore the published literature on the optimal induction and subsequent maintenance therapy for AIH.
Methods: We performed a systematic search on electronic databases MEDLINE (1950-07.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!